药动/药效模型的具体应用
A.Ollerstametal./JournalofPharmacologicalandToxicologicalMethods53(2006)174–183183
Acknowledgements
WewouldliketothankJennySo¨derstro¨m,AnnicaHa¨gg,NinaAhlstro¨mandMalinAntonssonforskilledtechnicalassistanceandanimalprocedures.
References
Abel,S.,Nichols,D.J.,Brearley,C.J.,&Eve,M.D.(2000).Effectof
cimetidineandranitidineonpharmacokineticsandpharmacodynamicsofasingledoseofdofetilide.BritishJournalofClinicalPharmacology,49,64–71.
Allen,M.J.,Nichols,D.J.,&Oliver,S.D.(2000).Thepharmacokineticsand
pharmacodynamicsoforaldofetilideaftertwicedailyandthreetimesdailydosing.BritishJournalofClinicalPharmacology,50,247–253.
Allen,M.J.,Oliver,S.D.,Newgreen,M.W.,&Nichols,D.J.(2002).
PharmacodynamiceffectofcontinuousvsintermittentdosingofdofetilideonQTinterval.BritishJournalofClinicalPharmacology,53,59–65.
Barrett,J.F.(2000).Moxifloxacinbayer.CurrentOpinioninInvestiga-tionalDrugs,1,45–51.
Brown,A.M.(2004).Drugs,hERGandsuddendeath.CellCalcium,35,
543–547.
Can,I.,Aytemir,K.,Kose,S.,&Oto,A.(2002).Physiologicalmechanisms
influencingcardiacrepolarizationandQTinterval.CardiacElectro-physiologyReview,6,278–281.
Crumb,W.,&Cavero,I.(1999).QTintervalprolongationbynon-cardiovasculardrugs:Issuesandsolutionsfornoveldrugdevelopment.PharmaceuticalScienceandTechnologyToday,2,270–280.
DePonti,F.,Poluzzi,E.,Cavalli,A.,Recanatini,M.,&Montanaro,N.
(2002).Safetyofnon-antiarrhythmicdrugsthatprolongtheQTintervalorinducetorsadedepointes:Anoverview.DrugSafety,25,263–286.DePonti,F.,Poluzzi,E.,&Montanaro,N.(2001).Organisingevidenceon
QTprolongationandoccurrenceofTorsadesdePointeswithnon-antiarrhythmicdrugs:Acallforconsensus.EuropeanJournalofClinicalPharmacology,57,185–209.
El-Sherif,N.,&Turitto,G.(2003).Torsadedepointes.CurrentOpinionin
Cardiology,18,6–13.
Gwilt,M.,Blackburn,K.J.,Burges,R.A.,Higgins,A.J.,Milne,A.A.,&
Solca,A.M.(1992).Electropharmacologyofdofetilide,anewclassIIIagent,inanaesthetiseddogs.EuropeanJournalofPharmacology,215,137–144.
Hammond,T.G.,Carlsson,L.,Davis,A.S.,Lynch,W.G.,MacKenzie,
I.,Redfern,W.S.,etal.(2001).Methodsofcollectingandevaluatingnon-clinicalcardiacelectrophysiologydatainthepharmaceuticalindustry:Resultsofaninternationalsurvey.CardiovascularResearch,49,741–750.
Hanada,E.,Ohtani,H.,Kotaki,H.,Sawada,Y.,Sato,H.,&Iga,T.(1999).
Pharmacodynamicanalysisoftheelectrocardiographicinteractionbetweendisopyramideanderythromycininrats.JournalofPharma-ceuticalSciences,88,234–240.
Johansson,L.,Sohn,D.,Thorberg,S.-O.,Jackson,D.M.,Kelder,D.,Larsson,
L.-G.,etal.(1997).Thepharmacologicalcharacterizationofanovelselective5-hydroxytryptamine1Areceptorantagonist,NAD-299.JournalofPharmacologicalExperimentalTherapeutics,283,216–225.
Johnson,B.F.,Cheng,S.L.,&Venitz,J.(2001).Transientkineticand
dynamicinteractionsbetweenverapamilanddofetilide,aclassIIIantiarrhythmic.JournalofClinicalPharmacology,41,1248–1256.Kleinbloesem,C.H.,VanBrummelen,P.,Danhof,M.,Faber,H.,Urquhart,
J.,&Breimer,D.D.(1987).Rateofincreaseintheplasmaconcentrationofnifedipineasamajordeterminantofitshemodynamiceffectsinhumans.ClinicalPharmacology&Therapeutics,41,26–30.
LeCoz,F.,Funck-Brentano,C.,Morell,T.,Ghadanfar,M.M.,&Jaillon,
P.(1995).Pharmacokineticandpharmacodynamicmodelingoftheeffectsoforalandintravenousadministrationsofdofetilideonventricularrepolarization.ClinicalPharmacology&Therapeutics,57,533–542.
Malik,M.(2001).Problemsofheartratecorrectioninassessmentofdrug-inducedQTintervalprolongation.JournalofCardiovascularElectro-physiology,12,411–420.
Malik,M.,Farbom,P.,Batchvarov,V.,Hnatkova,K.,&Camm,A.J.
(2002).RelationbetweenQTandRRintervalsishighlyindividualamonghealthysubjects:ImplicationsforheartratecorrectionoftheQTinterval.Heart,87,220–228.
Minematsu,T.,Ohtani,H.,Sato,H.,&Iga,T.(1999).SustainedQT
prolongationinducedbytacrolimusinguineapigs.LifeSciences,65,PL197–PL202.
Minematsu,T.,Ohtani,H.,Yamada,Y.,Sawada,Y.,Sato,H.,&Iga,T.
(2001).QuantitativerelationshipbetweenmyocardialconcentrationoftacrolimusandQTprolongationinguineapigs:Pharmacokinetic/phar-macodynamicmodelincorporatingasiteofadverseeffect.JournalofPharmacokineticsandPharmacodynamics,28,533–554.
Ohtani,H.,Taninaka,C.,Hanada,E.,Kotaki,H.,Sato,H.,Sawada,Y.,etal.
(2000).ComparativepharmacodynamicanalysisofQ–Tintervalprolongationinducedbythemacrolidesclarithromycin,roxithromycin,andazithromycininrats.AntimicrobialAgentsandChemotherapy,44,2630–2637.
Rampe,D.,Murawsky,M.K.,Grau,J.,&Lewis,E.W.(1998).The
antipsychoticagentsertindoleisahighaffinityantagonistofthehumancardiacpotassiumchannelHERG.JournalofPharmacologyandExperimentalTherapeutics,286,788–793.
Rasmussen,H.S.,Allen,M.J.,Blackburn,K.J.,Butrous,G.S.,&
Dalrymple,H.W.(1992).Dofetilide,anovelclassIIIantiarrhyth-micagent.JournalofCardiovascularPharmacology,20(Suppl2),S96–S105.
Raunig,D.,Depasquale,M.J.,Huang,C.H.,Winslow,R.,&Fossa,A.A.
(2001).StatisticalanalysisofQTintervalasafunctionofchangesinRRintervalintheconsciousdog.JournalofPharmacologicalandToxicologicalMethods,46,1–11.
Redfern,W.S.,Carlsson,L.,Davis,A.S.,Lynch,W.G.,MacKenzie,I.,
Palethorpe,S.,etal.(2003).Relationshipsbetweenpreclinicalcardiacelectrophysiology,clinicalQTintervalprolongationandtorsadedepointesforabroadrangeofdrugs:Evidenceforaprovisionalsafetymarginindrugdevelopment.CardiovascularResearch,58,32–45.
Segre,G.(1968).Kineticsofinteractionbetweendrugsandbiological
systems.Farmaco.EdizioneScientifica,23,907–918.
Sheiner,L.B.,Stanski,D.R.,Vozeh,S.,Miller,R.D.,&Ham,J.(1979).
Simultaneousmodelingofpharmacokineticsandpharmacodynamics:applicationtod-tubocurarine.ClinicalPharmacology&Therapeutics,25,358–371.
Smith,D.A.,Rasmussen,H.S.,Stopher,D.A.,&Walker,D.K.(1992).
Pharmacokineticsandmetabolismofdofetilideinmouse,rat,dogandman.Xenobiotica,22,709–719.
Vanoli,E.,Priori,S.G.,Nakagawa,H.,Hirao,K.,Napolitano,C.,Diehl,L.,
etal.(1995).Sympatheticactivation,ventricularrepolarizationandIkrblockade:Implicationsfortheantifibrillatoryefficacyofpotassiumchannelblockingagents.JournaloftheAmericanCollegeofCardiol-ogy,25,1609–1614.
Walker,D.K.,Alabaster,C.T.,Congrave,G.S.,Hargreaves,M.B.,
Hyland,R.,Jones,B.C.,etal.(1996).Significanceofmetabolisminthedispositionandactionoftheantidysrhythmicdrug,dofetilide.Invitrostudiesandcorrelationwithinvivodata.DrugMetabolismandDisposition,24,447–455.
Wang,J.,DellaPenna,K.,Wang,H.,Karczewski,J.,Connolly,T.M.,
Koblan,K.S.,etal.(2003).FunctionalandpharmacologicalpropertiesofcanineERGpotassiumchannels.AmericanJournalofPhysiology.HeartandCirculatoryPhysiology,284,H256–H267.
Effect of cobalt oxide on performance of Pd catalysts for lean-burn natural gas vehicles in the_专业资料。Avibeoiea all nl tanwww.cecitom sinedr.ecc一 。...
the QT interval (Nasir et al., 2004), ...Blood sampling was conducted in conscious and ...a time-dependent inhibitory effects induced by C....
Effect of Pd doping on the acetone-sensing properties of NdFeO_3_专业资料。IeninaJra firl,ealryadMaeil ntratolounloMneasMtlugntras VlmIeninaJra...
value of the corrected QT interval in the NSTE-...exercise-induced ST elevation (aVR excluded), ST...Effect of coronary angioplasty on electro...
Effect of Pd doping on the acetone-sensing properties of NdFeO_3_专业资料。IeninaJra firl,ealryadMaeil ntratolounloMneasMtlugntras VlmIeninaJra...
热门文档